Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis

Free Radical Research

Volumn 41, Issue 12, 2007, Pages 1301-1312

  Morgan, Philip E ^a   Sturgess, Allan D ^b   Hennessy, Annemarie ^a   Davies, Michael J ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

Apolipoprotein CIII; Atherosclerosis; Lupus nephritis; Protein carbonyls; Protein oxidation; Systemic lupus erythematosus

Indexed keywords

ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; APOLIPOPROTEIN C3; CARBONYL DERIVATIVE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; PROTEIN; PROTEOME; THIOL DERIVATIVE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC DIFFERENCE; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MASS SPECTROMETRY; OXIDATION; OXIDATIVE STRESS; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADULT; APOLIPOPROTEIN C-III; BIOLOGICAL MARKERS; BLOOD PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NEPHRITIS; OXIDATION-REDUCTION; PROTEOME;

EID: 37349086613     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.1080/10715760701684809     Document Type: Article

References (55)

1. Tsao, BP. (2003) The genetics of human systemic lupus erythematosus. Trends Immunol, 24, pp. 595-602.
2. Waszczykowska, E., Robak, E., Wozniacka, A., Narbutt, J., Torzecka, JD and Sysa-Jedrzejowska, A. (1999) Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation. Mediat Inflamm, 8, pp. 93-100.
3. Lahita, RG, Bradlow, HL, Ginzler, E., Pang, S. and New, M. (1987) Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum, 30, pp. 241-248.
4. Kaplan, MJ. (2004) Apoptosis in systemic lupus erythematosus. Clin Immunol, 112, pp. 210-218.
5. Westerweel, PE, Luyten, RKMAC, Koomas, HA, Derksen, RHWM and Verhaar, MC. (2007) Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum, 56, pp. 1384-1396.
6. Alves, JD and Ames, PRJ. (2003) Atherosclerosis, oxidative stress and auto-antibodies in systemic lupus erythematosus and primary antiphospholipid syndrome. Immunobiology, 207, pp. 23-28.
7. Kovacic, P. and Jacintho, JD. (2003) Systemic lupus erythematosus and other autoimmune diseases from endogenous and exogenous agents: Unifying theme of oxidative stress. Mini Rev Med Chem, 3, pp. 568-575.
8. Frostegard, J., Svenungsson, E., Wu, R., Gunnarsson, I., Lundberg, IE, Klareskog, L., Horkko, S. and Witztum, JL. (2005) Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum, 52, pp. 192-200.
9. Tam, LS, Li, EK, Leung, VYF, Griffith, JF, Benzie, IFF, Lim, PL, Whitney, B., Lee, VWY, Lee, KKC, Thomas, GN and Tomlinson, B. (2004) Effects of Vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: A double blind, placebo controlled pilot study. J Rheumatol, 32, pp. 275-282.
10. Evans, MD, Cooke, MS, Akil, M., Samanta, A. and Lunec, J. (2000) Aberrant processing of oxidative DNA damage in systemic lupus erythematosus. Biochem Biophys Res Comm, 273, pp. 894-898.
11. Lunec, J., Herbert, K., Blount, S., Griffiths, HR and Emery, P. (1994) 8-Hydroxydeoxyguanosine. A marker of oxidative damage in systemic lupus erythematosus. FEBS Lett, 348, pp. 131-138.
12. Davies, MJ. (2005) The oxidative environment and protein damage. Biochim Biophys Acta, 1703, pp. 93-109.
13. Morgan, PE, Sturgess, AD and Davies, MJ. (2005) Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum, 52, pp. 2069-2079.
14. Cross, J. and Jayne, D. (2005) Diagnosis and treatment of kidney disease. Best Pract Res Clin Rheumatol, 19, pp. 785-798.
15. Manger, K., Manger, P., Repp, R., Geisselbrecht, M., Geiger, A., Pfahlberg, A., Harrer, T. and Kalden, JR. (2002) Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis, 61, pp. 1065-1070.
16. Abu-Shakra, M., Urowitz, MB, Gladman, DD and Gough, J. (1995) Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol, 22, pp. 1265-1270.
17. Font, J., Ramos-Casals, M., Cervera, R., Garcia-Carrasco, M., Torras, A., Siso, A., Darnell, A. and Ingelmo, M. (2001) Cardiovascular risk factors and the long-term outcome of lupus nephritis. Q J Med, 91, pp. 19-26.
18. Serban, MG, Tanaseanu, S. and Bara, C. (1996) Oxidant stress and antioxidant protection in lupus nephropathy. Rom J Intern Med, 34, pp. 105-109.
19. Ho, CY, Wong, CK, Li, EK, Tam, LS and Lam, CWK. (2003) Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology, 42, pp. 117-122.
20. Oates, JC, Christensen, EF, Reilly, CM, Self, SE and Gilkeson, GS. (1999) Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: Correlation with disease activity. P Assoc Am Physician, 111, pp. 611-621.
21. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (1997) Hochberg MC. Letter to the Editor. Arthritis Rheum, 40, p. 1725.
22. Bombardier, C., Gladman, DD, Urowitz, MB, Caron, D., Chang, CH and in, SLE. Committee on Prognosis Studies (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum, 35, pp. 630-640.
23. Reinheckel, T., Korn, S., Mohring, S., Augustin, W., Halangk, W. and Schild, L. (2000) Adaptation of protein carbonyl detection to the requirements of proteome analysis demonstrated for hypoxia/reoxygenation in isolated rat liver mitochondria. Arch Biochem Biophys, 376, pp. 59-65.
24. Shevchenko, A., Wilm, M., Vorm, O. and Mann, M. (1996) Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal Chem, 68, pp. 850-858.
25. Verrills, NM, Walsh, BJ, Cobon, GS, Hains, PG and Kavallaris, M. (2003) Proteome analysis of Vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations. J Biol Chem, 278, pp. 45082-45093.
26. Rabilloud, T. (1990) Mechanisms of protein silver staining in polyacrylamide gels: A 10-year synthesis. Electrophoresis, 11, pp. 785-794.
27. Saunders, NFW, Ng, C., Raftery, M., Guilhaus, M., Goodchild, A. and Cavicchioli, R. (2006) Proteomic and computational analysis of secreted proteins with type I signal peptides from the Antarctic archaeon Methanococcoides burtonii. J Proteome Res, 5, pp. 2457-2464.
28. Fredenrich, A., Giroux, LM, Tremblay, M., Krimbou, L., Davignon, J. and Cohn, JS. (1997) Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: Comparison of the apoC-III to apoE ratio in different lipoprotein fractions. J Lipid Res, 38, pp. 1421-1432.
29. Tilly, P., Sass, C., Vincent-Viry, M., Aguillon, D., Siest, G. and Visvikis, S. (2003) Biological and genetic determinants of serum apoC-III concentration: Reference limits from the Stanislas cohort. J Lipid Res, 44, pp. 430-436.
30. Hodis, HN, Quismorio, FPJ, Wickham, E. and Blankenhorn, DH. (1993) The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol, 20, pp. 661-665.
31. Dalle-Donne, I., Giustarini, D., Colombo, R., Rossi, R. and Milzani, A. (2003) Protein carbonylation in human diseases. Trends Mol Med, 9, pp. 169-176.
32. Halliwell, B. and Gutteridge, JMC. (1999) Free radicals in biology and medicine, Oxford University Press, New York
33. Chevion, M., Berenshtein, E. and Stadtman, ER. (2000) Human studies related to protein oxidation: Protein carbonyl content as a marker of damage. Free Radical Res, 33, pp. S99-S108.
34. Hayashi, T., Era, S., Kawai, K., Imai, H., Nakamura, K., Onda, E. and Yoh, M. (2000) Observation for redox state of human serum and aqueous humor albumin from patients with senile cataract. Pathophysiology, 6, pp. 237-243.
35. Sogami, M., Era, S., Nagoka, S., Kuwata, K., Kida, K., Shigemi, J., Miura, K., Suzuki, E., Muto, Y., Tomita, E., Hayano, S., Sawada, S., Noguchi, K. and Miyata, S. (1985) High-performance liquid chromatographic studies on non-mercapt in equilibrium with mercapt conversion of human serum albumin. II. J Chromatogr, 332, pp. 19-27.
36. Kadota, K., Yui, Y., Hattori, R., Murohara, Y. and Kawai, C. (1991) Decreased sulfhydryl groups of serum albumin in coronary artery disease. Jpn Circ J, 55, pp. 937-941.
37. Beal, MF. (2002) Oxidative modified proteins in aging and disease. Free Radical Biol Med, 32, pp. 797-803.
38. Rottoli, P., Magi, B., Cianti, R., Bargagli, E., Vagaggini, C., Nikiforakis, N., Pallini, V. and Bini, L. (2005) Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics, 5, pp. 2612-2618.
39. Chapman, ML, Rubin, BR and Gracy, RW. (1989) Increased carbonyl content of proteins in synovial fluid from patients with rheumatoid arthritis. J Rheumatol, 16, pp. 15-18.
40. Lemarechal, H., Allanore, Y., Chenevier-Gobeaux, C., Kahan, A., Ekindjian, OG and Borderie, D. (2006) Serum protein oxidation in patients with rheumatoid arthritis and effects of infliximab therapy. Clin Chim Acta, 372, pp. 147-153.
41. van Dijk, KW, Rensen, PCN, Voshol, PJ and Havekes, LM. (2004) The role and mode of action of apolipoproteins CIII and AV: Synergistic actors in triglyceride metabolism?. Curr Opin Lipidol, 15, pp. 239-246.
42. Batal, R., Tremblay, M., Barrett, PHR, Jacques, H., Fredenrich, A., Mamer, O., Davignon, J. and Cohn, JS. (2000) Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res, 41, pp. 706-718.
43. Sacks, FM, Alaupovic, P., Moye, LA, Cole, TG, Sussex, B., Stampfer, MJ, Pfeffer, MA and Braunwald, E. (2000) VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation, 102, pp. 1886-1892.
44. Borba, EF and Bonfa, E. (1997) Dyslipoproteinemias in systemic lupus erythematosus: Influence of disease, activity, and anticardiolipin antibodies. Lupus, 6, pp. 533-539.
45. Nuttall, SL, Heaton, S., Piper, MK, Martin, U. and Gordon, C. (2003) Cardiovascular risk in systemic lupus erythematosus - evidence of increased oxidative stress and dyslipidaemia. Rheumatology, 42, pp. 758-762.
46. Karlsson, H., Leanderson, P., Tagesson, C. and Lindahl, M. (2005) Lipoproteomics I: Mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics, 5, pp. 551-565.
47. Karlsson, H., Leanderson, P., Tagesson, C. and Lindahl, M. (2005) Lipoproteomics II: Mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics, 5, pp. 1431-1445.
48. Asanuma, Y., Chung, CP, Oeser, A., Shintani, A., Stanley, E., Raggi, P. and Stein, CM. (2006) Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: Relationship to cardiovascular risk factors. J Rheumatol, 33, pp. 539-545.
49. Eaton, CB. (2005) Traditional and emerging risk factors for cardiovascular disease. Prim Care Clin Office Pract, 32, pp. 963-976.
50. Karrar, A., Sequeira, W. and Block, JA. (2001) Coronary artery disease in systemic lupus erythematosus: A review of the literature. Semin Arthritis Rheum, 30, pp. 436-443.
51. Delanghe, JR and Langlois, MR. (2001) Hemopexin: A review of biological aspects and the role in laboratory medicine. Clin Chim Acta, 312, pp. 13-23.
52. Steel, LF, Trotter, MG, Nakajima, PB and Mattu, TS. (2003) Efficient and specific removal of albumin from human serum samples. Mol Cell Proteomics, 2, pp. 262-270.
53. Cho, SY, Lee, EY, Lee, JS, Kim, HY, Park, JM, Kwon, MS, Park, YK, Lee, HJ, Kang, MJ, Kim, JY, Yoo, JS, Park, SJ, Cho, JW, Kim, HS and Paik, YK. (2005) Efficient prefractionation of low-abundance proteins in human plasma and construction of a two-dimensional map. Proteomics, 5, pp. 3386-3396.
54. Frostegard, J. (2005) SLE, atherosclerosis and cardiovascular disease. J Intern Med, 257, pp. 485-495.
55. Esdaile, JM, Abrahamowicz, M., Grodzicky, T., Li, Y., Panaritis, C., Berger, R du, Cote, R., Grover, SA, Fortin, PR, Clarke, AE and Senecal, JL. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum, 44, pp. 2331-2337.